We are live on
!
Find out more
PCM
Prelude Capital Management Portfolio holdings
AUM
$1.31B
1-Year Est. Return
62.02%
This Fund
S&P 500
This Quarter
Est. Return
+16.88%
1 Year Est. Return
+62.02%
3 Year Est. Return
+164.16%
5 Year Est. Return
+274.13%
10 Year Est. Return
+2,470.2%
AUM
$1.03B
AUM Growth
-$287M
(-22%)
Cap. Flow
-$398M
Cap. Flow
% of AUM
-38.68%
Top 10 Holdings %
Top 10 Hldgs %
14.04%
Holding
1,478
New
335
Increased
269
Reduced
346
Closed
503
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$12.3M |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$10.9M |
| 3 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$10.4M |
| 4 |
Tesla
TSLA
|
+$9.96M |
| 5 |
NVIDIA
NVDA
|
+$8.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$10.4M |
| 2 |
Broadcom
AVGO
|
+$9.33M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$8.68M |
| 4 |
DESP
Despegar.com
DESP
|
+$7.15M |
| 5 |
Oracle
ORCL
|
+$6.74M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.86% |
| 2 | Consumer Discretionary | 12.74% |
| 3 | Healthcare | 12.34% |
| 4 | Communication Services | 10.34% |
| 5 | Industrials | 8.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
751
Sarepta Therapeutics
SRPT
$1.78B
| $225K | 0.02% |
+13,135
| New | +$560K |
|
752
Veralto
VLTO
$23.8B
| $224K | 0.02% |
+2,222
| New | +$214K |
|
|
OPOF
753
DELISTED
Old Point Financial
OPOF
| $224K | 0.02% |
+5,708
| New | +$221K |
|
754
Denali Therapeutics
DNLI
$3.94B
| $223K | 0.02% |
+15,940
| New | +$224K |
|
755
Leonardo DRS
DRS
$12B
| $223K | 0.02% |
4,789
-1,590
| -25% | -$63.9K |
|
756
United States Lime & Minerals
USLM
$3.47B
| $222K | 0.02% |
2,229
-269
| -11% | -$26.3K |
|
757
AbCellera Biologics
ABCL
$2.81B
| $222K | 0.02% |
+64,813
| New | +$161K |
|
758
PUT
State Street Consumer Staples Select Sector SPDR ETF
XLP
$14.7B
| $222K | 0.02% |
925
-93,275
| -99% | -$7.57M |
|
759
Saic
SAIC
$5.37B
| $222K | 0.02% |
+1,970
| New | +$224K |
|
760
Methanex
MEOH
$4.26B
| $222K | 0.02% |
6,701
-327
| -5% | -$10.5K |
|
761
Encompass Health
EHC
$12.4B
| $221K | 0.02% |
+1,805
| New | +$206K |
|
|
NGD
762
DELISTED
New Gold Inc
NGD
| $221K | 0.02% |
+44,656
| New | +$183K |
|
763
CAVA Group
CAVA
$7.04B
| $221K | 0.02% |
2,619
-3,071
| -54% | -$262K |
|
764
Blackrock
BLK
$175B
| $220K | 0.02% |
+210
| New | +$199K |
|
765
Commerce Bancshares
CBSH
$8.46B
| $220K | 0.02% |
+3,721
| New | +$218K |
|
766
Kelly Services Class A
KELYA
$539M
| $220K | 0.02% |
+18,800
| New | +$222K |
|
767
Eastman Chemical
EMN
$8.35B
| $220K | 0.02% |
2,945
-558
| -16% | -$43.8K |
|
768
Teradyne
TER
$57.7B
| $220K | 0.02% |
+2,445
| New | +$195K |
|
769
FB Financial Corp
FBK
$3.03B
| $220K | 0.02% |
4,853
-1,305
| -21% | -$56.7K |
|
770
Generac Holdings
GNRC
$12.4B
| $220K | 0.02% |
+1,533
| New | +$187K |
|
|
BIOA
771
BioAge Labs
BIOA
$522M
| $219K | 0.02% |
53,139
+35,639
| +204% | +$144K |
|
772
Zscaler
ZS
$28.5B
| $219K | 0.02% |
699
-1,260
| -64% | -$314K |
|
773
Chubb
CB
$134B
| $219K | 0.02% |
+756
| New | +$218K |
|
774
Seneca Foods Class A
SENEA
$1.21B
| $218K | 0.02% |
+2,150
| New | +$193K |
|
|
IPG
775
DELISTED
Interpublic Group of Companies
IPG
| $217K | 0.02% |
8,878
-86,854
| -91% | -$2.11M |
|
Similar funds
PFBT
CCP
SP
HCS
SPC
GPCM
MCM
CC
Prelude Capital Management's Q2 2025 Portfolio in Review
As of Q2 2025, Prelude Capital Management held 1,478 positions worth $1.03B, down 22% from $1.32B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Prelude Capital Management withdrew a net $398M in Q2 2025, closing 503 positions and reducing 346 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $10.4M position sold in full.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 13% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Prelude Capital Management opened a new position in Alphabet (Google) Class C worth $11.7M.
- Prelude Capital Management's largest Q2 2025 buy was Alphabet (Google) Class C: 65,723 shares worth $11.7M.
- Prelude Capital Management added most to Meta Platforms (Facebook) in Q2 2025, an estimated $12.3M increase.
- Prelude Capital Management's biggest Q2 2025 reduction was Broadcom, cutting an estimated $9.33M.
- Prelude Capital Management fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $10.4M.
- Prelude Capital Management's ten largest holdings make up 14% of its $1.03B portfolio in Q2 2025.
- Prelude Capital Management opened 335 new positions and closed 503 in Q2 2025.
- Prelude Capital Management's portfolio value fell 22% quarter-over-quarter to $1.03B.
Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.